Dr. Helen Genova awarded grant for novel emotional processing study in multiple sclerosis
(Kessler Foundation) Helen Genova, Ph.D., Assistant Director of Neuropsychology&Neuroscience Research at Kessler Foundation, has been awarded a $44,000 grant from the National Multiple Sclerosis Society. The grant funds her research on emotional processing deficits in people with multiple sclerosis, an autoimmune degenerative disease of the central nervous system associated with significant behavioral and emotional sequelae.
Publication date: Available online 14 October 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Cinzia Tiloca, Melissa Sorosina, Federica Esposito, Silvia Peroni, Claudia Colombrita, Nicola Ticozzi, Antonia Ratti, Filippo Martinelli Boneschi, Vincenzo Silani
Publication date: Available online 12 October 2018Source: Autoimmunity ReviewsAuthor(s): Gwendoline Montes Diaz, Raymond Hupperts, Judith Fraussen, Veerle SomersAbstractMultiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system (CNS) in which demyelination and neurodegeneration occurs. The immune system of MS patients is characterized by a dysregulation in the balance between pro- and anti-inflammatory immune cells, whereby both the innate and adaptive immune system are involved. Dimethyl fumarate (DMF) was licensed in 2013 as an oral first-line therapy for relapsing-remitting (RR)MS...
AbstractIdentification of non-invasive biomarkers of disease progression in multiple sclerosis (MS) is critically needed for monitoring the disease progression and for effective therapeutic interventions. Urine is an attractive source for non-invasive biomarkers because it is easily obtained in the clinic. In search of a urine metabolite signature of progression in chronic experimental autoimmune encephalomyelitis (EAE), we profiled urine at the chronic stage of the disease (day 45 post immunization) by global untargeted metabolomics. Using a combination of high-throughput liquid-and-gas chromatography with mass spectromet...
This study represents the first report of the miR-455-5p acts as an anti-inflammatory role in MS, at least partially through targeting MyD88 and REL. This study may provide imp ortant information for the use of miR-455-5p as a novel strategy to improve the severity of disease and control inflammation and attack in MS patients.
Publication date: January 2019Source: Multiple Sclerosis and Related Disorders, Volume 27Author(s): Giorgio Biasiotto, Isabella Zanella
Multiple sclerosis is an immune-mediated autoimmune disease of the central nervous system that develops in genetically susceptible individuals and likely requires environmental triggers. The autoantigens and molecular mimics triggering the autoimmune response in multiple sclerosis remain incompletely understood. By using a brain-infiltrating CD4+ T cell clone that is clonally expanded in multiple sclerosis brain lesions and a systematic approach for the identification of its target antigens, positional scanning peptide libraries in combination with biometrical analysis, we have identified guanosine diphosphate (GDP)–...
Publication date: Available online 4 October 2018Source: Multiple Sclerosis and Related DisordersAuthor(s): Giorgio Biasiotto, Isabella Zanella
ConclusionThis patient likely has autoimmune encephalitis associated with elevated N-type calcium channel antibodies. This case highlights the clinical significance of N-type calcium channel antibodies and the importance of correctly diagnosing patients with antibody mediated disease that may very well mimic more common neurologic diseases such as multiple sclerosis (MS).
ConclusionThe concurrence of JIA and multiple sclerosis (MS) has been reported in only two adult cases and not in the pediatric population. While JIA and MS are two distinct chronic inflammatory diseases, immunogenetic predisposition and common environmental triggers might be involved.
Conclusion: Based on the data that Tα1 and Tβ4 act as anti-inflammatory molecules and as inducers of myelin repair and neuronal protection, respectively, a possible therapeutic application in MS for Tα1 and Tβ4 alone or combined with other approved drugs may be envisaged. This approach is reasonable in light of the current clinical usage of Tα1 and data demonstrating the safety, tolerability and efficacy of Tβ4 in clinical practice.